Sakurai K, Motokawa I, Ando T, Ohmura Y, Saito K, Matsunaga K, Fujii T, Yoshikumi C, Nomoto K
Biomedical Research Laboratories, Kureha Chemical Industry Co., Ltd., Tokyo, Japan.
In Vivo. 1993 Mar-Apr;7(2):175-9.
PSK, a protein-bound polysaccharide derived from basidiomycetes, is a biological response modifier that exhibits a variety of activities following oral administration, including prevention of infection. In this study, the effects of oral administration of this drug on microbial flora of tumor-bearing mice were examined. Numbers of Staphylococcus, Streptococcus and Pseudomonas were increased, and those of Bifidobacterium and Lactobacillus were reduced in fresh feces of mice from later than 9 weeks after inoculation of sarcoma 180. However, these changes were prevented by oral administration of PSK. In mice bearing sarcoma 180, the increases in numbers of Staphylococcus and Pseudomonas and the decrease in those of Bifidobacterium were further enhanced by intraperitoneal administration of anticancer agent mitomycin C, but such changes were suppressed by oral administration of PSK. These results suggest that PSK has a preventive effect against abnormal conditions of the intestinal flora induced by tumor inoculation or the administration of anticancer agents.
PSK是一种从担子菌中提取的蛋白结合多糖，是一种生物反应调节剂，口服后具有多种活性，包括预防感染。在本研究中，检测了口服该药物对荷瘤小鼠微生物菌群的影响。接种肉瘤180后9周以后的小鼠新鲜粪便中，葡萄球菌、链球菌和假单胞菌数量增加，双歧杆菌和乳酸杆菌数量减少。然而，口服PSK可防止这些变化。在荷肉瘤180小鼠中，腹腔注射抗癌剂丝裂霉素C可进一步增强葡萄球菌和假单胞菌数量的增加以及双歧杆菌数量的减少，但口服PSK可抑制这些变化。这些结果表明，PSK对肿瘤接种或抗癌剂给药引起的肠道菌群异常状况具有预防作用。
